Haykal, T., Yarla, N., DeVito, N., Beasley, G., Salama, A., Hanks, B., & Theivanthiran, B. (2022). 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. In Regular and Young Investigator Award Abstracts (pp. A24–A24). BMJ Publishing Group Ltd. https://doi.org/10.1136/jitc-2022-sitc2022.0022

Haykal, Tarek, Nagendra Yarla, Nicholas DeVito, Georgia Beasley, April Salama, Brent Hanks, and Balamayooran Theivanthiran. “22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients.” In Regular and Young Investigator Award Abstracts, A24–A24. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/jitc-2022-sitc2022.0022.

Haykal T, Yarla N, DeVito N, Beasley G, Salama A, Hanks B, et al. 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. In: Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022. p. A24–A24.

Haykal, Tarek, et al. “22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients.” Regular and Young Investigator Award Abstracts, BMJ Publishing Group Ltd, 2022, pp. A24–A24. Crossref, doi:10.1136/jitc-2022-sitc2022.0022.

Haykal T, Yarla N, DeVito N, Beasley G, Salama A, Hanks B, Theivanthiran B. 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients. Regular and Young Investigator Award Abstracts. BMJ Publishing Group Ltd; 2022. p. A24–A24.